Company intelligence / Profile preview

BENESTE

Hayward, California, United Statesabr.business.gov.au ↗

Ownership: Private
Development stage: Other

Overview

Benitec Biopharma has initiated a Phase 1b/2a dose escalation study of BB 301 for OPMD. The company’s proprietary ddRNAi platform enables single-administration gene silencing and replacement. No published late-stage results yet; enrollment ongoing as of mid 2024.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Gene therapyRNA therapySmall molecule
Industry: Biotech

Partnerships

Suvretta Capital led $40M PIPE financing in April 2024; no major pharma partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on BENESTE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BENESTE.

Explore the full profile